News for dentistry professionals
10 Mar 2020
Pulcini A, Bollaín J, Sanz-Sánchez I, Figuero E, Alonso B, Sanz M, Herrera D. Clinical effects of the adjunctive use of a 0.03% chlorhexidine and 0.05% cetylpyridinium chloride mouth rinse in the management of peri-implant diseases: a randomized clinical trial. J Clin Periodontol 2019 Mar; 46 (3): 342-353.
Peri-implant Mucositis (PiM) is very common and there is published evidence of its treatment through mechanical control of biofilm and adjuvant chemical antimicrobials.
The use of low concentration chlorhexidine (CHX) mouthwashes, combined with cetylpyridinium chloride (CPC) has not been previously tested in PiM management.
To evaluate the efficacy in the treatment of PiM of a 0.03% CHX and 0.05% CPC mouthrinse as a complement to the mechanical removal of plaque performed by both the professional during maintenance visits and by the patient daily.
This randomised, double-blind clinical trial included patients who showed PiM in at least one implant.
The subjects received professional prophylaxis at the beginning of the trial and after six months and were instructed on regular oral hygiene and rinsing practices with the test product or with placebo mouthwash, twice a day and for one year.
Clinical, radiographic and microbiological results were evaluated at the beginning of the study, after six months and after twelve months. The resolution of the disease was defined as the absence of Bleeding on Probing (BOP).
Data were analysed applying repeated measures ANOVA (Analysis of Variance), Student's t and chi-square test.
The trial included 54 patients, of which 46 attended the final visit (22 in the control group and 24 in the test group). The test group showed a 24.49% greater reduction in BOP at the vestibular sites (95% confidence interval [3.65-45.34%]; p = 0.002) than the controls. 58.3% of the implants in the test group and 50% of those in the control group showed healthy peri-implant tissues at the final visit (p> 0.05).
The use of the test mouthwash showed some additional benefits in the treatment of PiM. The complete resolution of the disease could not be achieved in all cases.
18 Jun 2020
A clinical trial has shown the regenerative properties of PERIO·AID® Bioadhesive gel after surgical removal of two third molars. Evaluation* of the…
27 Jun 2019
This study will be useful for the future development of antibacterial strategies preventing incidence and progression of peri-implantitis in patients…
25 Feb 2019
DENTAID presents new research at EuroPerio9 into the effect of the microorganism Solobacterium moorei on oral biofilm and its implication in bad…
Sign up for the DENTAID Expertise newsletter
Sign up for the newsletter
|Data controller||DENTAID, S.L. LABORATORIOS DE PREVENCIÓN E HIGIENE BUCAL, SLU (“PHB”).|
|Purpose of data processing||To respond to a query from the interested party with the advice of a specialist.|
|Legitimisation of data processing||Your consent to process your personal data.|
|Recipients of disclosure or transfer||Data is not disclosed or transferred internationally.|
|Rights of the interested persons||To access, rectify and delete their data, and to exercise other rights as set out in the additional information.|
|Additional information||You can consult additional and detailed information on data protection at this link.|
The content shown below corresponds to Spain and to products sold under country-specific registration.OK